The deal extends AbbVie’s commitment to the psychedelics space and depression, after emraclidine’s high-profile flop in schizophrenia last November.
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B Read More »
LB Pharma will test the IPO market to seek funding for a Phase III-ready schizophrenia asset.
Biotech Finally Has an IPO After Months-Long Freeze Read More »
On Friday, a Maryland district judge paused the creation of a fine for individuals who automatically reenroll in ACA plans, a policy making it harder for people to receive subsidies and other key elements of a controversial final rule from July.
Judge stays provisions of Trump administration rule overhauling ACA Read More »
The company has lost 57 unique acute care customers in the past three years, 12 of which are larger health systems with more than 1,000 beds, according to a report by Klas Research.
Oracle Health’s market share declined ‘substantially’ after Cerner buy: report Read More »
From M&A to MDUFA and the developing market in renal denervation, MedTech Dive covers the key issues for the industry to watch in the final months of the year.
Top roles at Intuitive, Boston Scientific, Dexcom and others changed hands this year. Read MedTech Dive’s roundup for all the details.
Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare disease called Alagille syndrome.
Arnatar Debuts With $52M To Advance RNA Therapies That Go Beyond Silencing Read More »
The data breach is one of the largest healthcare incidents reported to federal regulators this year.
Ransomware attack on DaVita exposes data from 2.7M Read More »
Thousands of employees across the Department of Health and Human Services are set to lose their collective bargaining rights in a move that American Federation of Government Employees national president Everett Kelley called “illegal and immoral.”
The FDA Adverse Event Reporting System, which Commissioner Marty Makary called “clunky,” previously published updates on a quarterly basis.
FDA To Publish Drug-Related Adverse Event Reports Daily Read More »
